Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.32 |
| ▸ | BLM | P54132 | 1/20 | 0.32 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.32 |
| ▸ | LDHA | P00338 | 1/20 | 0.30 |
| ▸ | LDHB | P07195 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28651759 | 1.00 | TSHR (0.35) | TSHRLMNAALOX15BLMPMP22 | |
| SCHEMBL14638267 | 1.00 | TSHR (0.35) | TSHRLMNAALOX15BLMPMP22 | |
| SCHEMBL2237340 | 0.76 | LMNA (0.47) | TSHRLMNAALOX15BLMPMP22 | |
| SCHEMBL6206612 | 0.74 | CES1 (0.48) | TSHRALOX15 | |
| SCHEMBL6206987 | 0.71 | CES1 (0.52) | TSHRALOX15 | |
| SCHEMBL18424789 | 0.71 | LMNA (0.41) | TSHRLMNAALOX15BLMPMP22 | |
| SCHEMBL11229973 | 0.71 | LMNA (0.41) | TSHRLMNAALOX15BLMPMP22 | |
| SCHEMBL11229978 | 0.71 | LMNA (0.41) | TSHRLMNAALOX15BLMPMP22 | |
| Chloroacetic Acid SCHEMBL5237087 | 0.68 | — | — | |
| SCHEMBL15148211 | 0.67 | LMNA (0.37) | LMNAALOX15BLMPMP22LDHA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8969363-B2 | Heterocyclic compounds and uses thereof | INFINITY PHARMACEUTICALS, INC. (US) | 2015-03-03 | — | — | US | disclosed |
| US-20130029982-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | INTELLIKINE, LLC (US) | 2013-01-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130029982-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | PIK3CA, PIK3CD, PIK3CB | TSHR 4224/4885LMNA 1475/4885ALOX15 1896/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.